Imiquimod and Chlamydia trachomatis Infection in Mice
Author Information
Author(s): Kyle H. Ramsey, Namir Shaba, Kevin P. Cohoon, Kevin A. Ault
Primary Institution: Department of Microbiology, Chicago College of Osteopathic Medicine, Midwestern University
Hypothesis
We postulated that either oral or vaginal administration of the immune response modifier imiquimod would decrease vaginal shedding of Chlamydia trachomatis in a murine model.
Conclusion
Imiquimod has no efficacy in controlling Chlamydia trachomatis infection in the murine model.
Supporting Evidence
- There was no significant difference in the course of infection between imiquimod-treated and control mice.
- IgG subclass antibody responses were unaffected by imiquimod treatment.
- Both treatment groups displayed a vigorous Th1 response with no shift to Th2 polarization.
Takeaway
The study tested a medicine called imiquimod to see if it could help mice with a type of infection, but it didn't work.
Methodology
Female BALB/c mice were infected with Chlamydia trachomatis and treated with imiquimod either orally or vaginally, with infection monitored through cervical-vaginal swabs.
Limitations
The study did not assess pathological outcomes after infection resolution, and the effects of imiquimod may have been masked by the strong natural immune response.
Participant Demographics
Female BALB/c mice, aged six to eight weeks.
Want to read the original?
Access the complete publication on the publisher's website